MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics Inc MGNX
$3.69
▼ -2.38%
($-0.09)
🗓️ Earnings Next Week
Open
$3.79
Prev Close
$3.78
Day Range
$3.61 – $3.80
52W Range
$1.29 – $5.08
Market Cap
$234.55M
Beta
1.20
EPS (TTM)
$-1.11
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-10 |
| Shares Out. | 63,560,000 |
| Website | macrogenics.com/ ↗ |
| Phone | 13012515172 |
| Employees | 293 |
| Revenue | $20.8M |
| Gross Profit | $11.2M |
| Net Income | -$36.8M |
| Free Cash Flow | -$71.7M |
| Total Assets | $217.9M |
| Total Liabilities | $196.7M |
| Equity | $21.2M |
About MacroGenics Inc
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
MacroGenics Inc is a publicly traded company under the ticker symbol MGNX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)